Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma. Issue 5 (16th May 2022)

• Record Type: Journal Article
• Authors: Roy, Amitesh Chandra; Abbas, M. Nazim; Price, Timothy Jay; Singhal, Nimit; Vatandoust, Sina; Leung, John; Kichenadasse, Ganessan; Koczwara, Bogda; Sukumaran, Shawgi; Kumar, Rajiv; Woodman, Richard; Scott-Hoy, Alex; Karapetis, Christos Stelios
• Is Part Of: Pancreas. Volume 51:Issue 5(2022)
• Page Start: 490
• Page End: 495
• Publication Date: 2022-05-16
• Subjects: nab-paclitaxel -- radiotherapy -- locally advanced pancreatic cancer; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000002065
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Objectives: Nab-paclitaxel has radiosensitizing antitumor efficacy in pancreatic cancer. We aimed to establish maximum tolerated dose (MTD) of nab-paclitaxel with radiotherapy in unresectable locally advanced pancreatic cancer. Methods: In a phase I dose escalation trial patients received weekly nab-paclitaxel for 6 weeks with external beam radiotherapy (EBRT). 3 + 3 design was used with nab-paclitaxel doses: 25 mg/m 2 (cohort 1), 50 mg/m 2 (cohort 2), 75 mg/m 2 (cohort 3), and 100 mg/m 2 (cohort 4). Primary endpoint was MTD. Secondary objectives were progression-free survival and overall survival. Results: Fourteen patients were recruited. Median age was 69 years (range, 40–86). Grade 1/2 toxicities were nausea (93%), vomiting (54%), diarrhea (57%), and fatigue (69%). There were no dose limiting toxicities (DLT) in cohorts 1 to 3. In cohort 4, DLTs of febrile neutropenia and enterocolitis were observed in patient 1. Subsequent DLT of febrile neutropenia and enterocolitis occurred in patient 5 in the expanded cohort. Following chemoradiotherapy median progression-free survival was 4.7 months (95% confidence interval, 2.5–27.5) and median overall survival was 10.8 months (95% confidence interval, 6.37–25.2). Conclusions: Nab-paclitaxel and EBRT was well-tolerated at doses below 100 mg/m 2 . The MTD and recommended phase II study dose for nab-paclitaxel with EBRT is 75 mg/m 2 in this disease.